Updated on June 12, 2022
HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
(HealthDay News) -- Here are the latest clinical trials, courtesy of Thomson CenterWatch:
COPD (Chronic Obstructive Pulmonary Disease) or Emphysema
This study will evaluate an investigational device for people with COPD. Eligible participants must be 40 or older and be current or former smokers. The study consists of six clinic visits over approximately 15-18 weeks.
The research site is in St. Louis, Mo.
Human Papillomavirus (HPV)
Have you been told that you have cervical HPV (human papillomavirus)? If so, you may qualify for a study to evaluate a drug that may speed healing of cervical HPV infection. This drug is applied intravaginally in the form of a gel. Women 18-40 may be eligible who have a uterine cervical sample that is HR HPV positive, have not received an active HPV vaccine at any time prior to the screening visit, and do not have evidence of genital, peri-anal or vaginal warts.
The research site is in Nashville, Tenn.
Diabetes - Type 2
This trial will evaluate the effectiveness and safety of an investigational medication for adults with type 2 diabetes. Volunteers 18-80 who have been on a stable dose of metformin of at least 1,000 mg/day for at least the prior four weeks may be included.
The research site is in Gainesville, Fla.
Copyright 2007 Thomson CenterWatch. All rights reserved.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at email@example.com with any questions.